C2 GROUP, LLC for BIOTECHNOLOGY INDUSTRY ORGANIZATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS CRAWFORD | — |
| ROLAND NELSON LITTERST | — |
Health Issues HCR
Oppose Independent Payment Advisory Board (IPAB). Medicare Part B Drug Reimbursement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROLAND NELSON LITTERST | — |
Budget/Appropriations BUD
Monitor Appropriations and Continuing Resolutions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROLAND NELSON LITTERST | — |
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.